Trial Profile
Xarelto on Prevention of Stroke and Non-Central Nervous Systemic (CNS) Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation (NVAF)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Dec 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism; Stroke
- Focus Adverse reactions
- Acronyms XARENAL
- Sponsors Bayer
- 21 Dec 2021 Status changed from active, no longer recruiting to completed.
- 27 Aug 2021 Planned primary completion date changed from 31 Jul 2021 to 28 Jul 2021.
- 02 Sep 2020 Status changed from recruiting to active, no longer recruiting.